Cargando…

Impact of comorbidities on hospitalised Syrian patients with COVID-19: a retrospective study

OBJECTIVES: This study aims to compare the clinical manifestations, laboratory findings, outcomes and overall survival time of patients with COVID-19 with and without comorbidities. DESIGN: Retrospective design. SETTING: This study was undertaken at two hospitals in Damascus. PARTICIPANTS: A total o...

Descripción completa

Detalles Bibliográficos
Autores principales: Najjar, Michel, Albuaini, Sara, Fadel, Mohammad, Aljbawi, Ahmad, AlAwad, Yara, Mohsen, Fatema
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10030286/
https://www.ncbi.nlm.nih.gov/pubmed/36940947
http://dx.doi.org/10.1136/bmjopen-2022-068849
_version_ 1784910328204623872
author Najjar, Michel
Albuaini, Sara
Fadel, Mohammad
Aljbawi, Ahmad
AlAwad, Yara
Mohsen, Fatema
author_facet Najjar, Michel
Albuaini, Sara
Fadel, Mohammad
Aljbawi, Ahmad
AlAwad, Yara
Mohsen, Fatema
author_sort Najjar, Michel
collection PubMed
description OBJECTIVES: This study aims to compare the clinical manifestations, laboratory findings, outcomes and overall survival time of patients with COVID-19 with and without comorbidities. DESIGN: Retrospective design. SETTING: This study was undertaken at two hospitals in Damascus. PARTICIPANTS: A total of 515 Syrian patients met the inclusion criterion, laboratory-confirmed COVID-19 infection following the Centers for Disease Control and Prevention. Exclusion criteria were suspected and probable cases that were not confirmed with a positive reverse transcription-PCR assay, and patients who self-discharged from the hospital against medical advice. PRIMARY AND SECONDARY OUTCOME MEASURES: First, assess the impacts of comorbidities on COVID-19 infection in four areas (clinical manifestations, laboratory findings, severity and outcomes). Second, calculate the overall survival time for patients with COVID-19 with comorbidities. RESULTS: Of 515 patients included, 316 (61.4%) were male and 347 (67.4%) had at least one coexisting chronic disease. Patients with comorbidities compared with no comorbidities were more vulnerable to poor outcomes such as severe infection (32.0% vs 9.5%, p<0.001), severe complications (34.6% vs 9.5%, p<0.001), the need for mechanical ventilation (28.8% vs 7.7%, p<0.001) and death (32.0% vs 8.3%, p<0.001). Multiple logistic regression showed that age ≥65 years old, positive smoking history, having ≥2 comorbidities and chronic obstructive pulmonary disease were risk factors linked to severe COVID-19 infection in patients with comorbidities. Overall survival time was lower among patients with comorbidities (vs no comorbidities), patients with ≥2 comorbidities (vs one comorbidity), and patients with hypertension, chronic obstructive pulmonary disease, malignancy or obesity (vs other comorbidities) (p<0.05). CONCLUSION: This study revealed that COVID-19 infection had poor outcomes among those with comorbidities. Severe complications, mechanical ventilation usage and death were more prevalent among patients with comorbidities compared with those with no comorbidities.
format Online
Article
Text
id pubmed-10030286
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-100302862023-03-22 Impact of comorbidities on hospitalised Syrian patients with COVID-19: a retrospective study Najjar, Michel Albuaini, Sara Fadel, Mohammad Aljbawi, Ahmad AlAwad, Yara Mohsen, Fatema BMJ Open Infectious Diseases OBJECTIVES: This study aims to compare the clinical manifestations, laboratory findings, outcomes and overall survival time of patients with COVID-19 with and without comorbidities. DESIGN: Retrospective design. SETTING: This study was undertaken at two hospitals in Damascus. PARTICIPANTS: A total of 515 Syrian patients met the inclusion criterion, laboratory-confirmed COVID-19 infection following the Centers for Disease Control and Prevention. Exclusion criteria were suspected and probable cases that were not confirmed with a positive reverse transcription-PCR assay, and patients who self-discharged from the hospital against medical advice. PRIMARY AND SECONDARY OUTCOME MEASURES: First, assess the impacts of comorbidities on COVID-19 infection in four areas (clinical manifestations, laboratory findings, severity and outcomes). Second, calculate the overall survival time for patients with COVID-19 with comorbidities. RESULTS: Of 515 patients included, 316 (61.4%) were male and 347 (67.4%) had at least one coexisting chronic disease. Patients with comorbidities compared with no comorbidities were more vulnerable to poor outcomes such as severe infection (32.0% vs 9.5%, p<0.001), severe complications (34.6% vs 9.5%, p<0.001), the need for mechanical ventilation (28.8% vs 7.7%, p<0.001) and death (32.0% vs 8.3%, p<0.001). Multiple logistic regression showed that age ≥65 years old, positive smoking history, having ≥2 comorbidities and chronic obstructive pulmonary disease were risk factors linked to severe COVID-19 infection in patients with comorbidities. Overall survival time was lower among patients with comorbidities (vs no comorbidities), patients with ≥2 comorbidities (vs one comorbidity), and patients with hypertension, chronic obstructive pulmonary disease, malignancy or obesity (vs other comorbidities) (p<0.05). CONCLUSION: This study revealed that COVID-19 infection had poor outcomes among those with comorbidities. Severe complications, mechanical ventilation usage and death were more prevalent among patients with comorbidities compared with those with no comorbidities. BMJ Publishing Group 2023-03-20 /pmc/articles/PMC10030286/ /pubmed/36940947 http://dx.doi.org/10.1136/bmjopen-2022-068849 Text en © Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Infectious Diseases
Najjar, Michel
Albuaini, Sara
Fadel, Mohammad
Aljbawi, Ahmad
AlAwad, Yara
Mohsen, Fatema
Impact of comorbidities on hospitalised Syrian patients with COVID-19: a retrospective study
title Impact of comorbidities on hospitalised Syrian patients with COVID-19: a retrospective study
title_full Impact of comorbidities on hospitalised Syrian patients with COVID-19: a retrospective study
title_fullStr Impact of comorbidities on hospitalised Syrian patients with COVID-19: a retrospective study
title_full_unstemmed Impact of comorbidities on hospitalised Syrian patients with COVID-19: a retrospective study
title_short Impact of comorbidities on hospitalised Syrian patients with COVID-19: a retrospective study
title_sort impact of comorbidities on hospitalised syrian patients with covid-19: a retrospective study
topic Infectious Diseases
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10030286/
https://www.ncbi.nlm.nih.gov/pubmed/36940947
http://dx.doi.org/10.1136/bmjopen-2022-068849
work_keys_str_mv AT najjarmichel impactofcomorbiditiesonhospitalisedsyrianpatientswithcovid19aretrospectivestudy
AT albuainisara impactofcomorbiditiesonhospitalisedsyrianpatientswithcovid19aretrospectivestudy
AT fadelmohammad impactofcomorbiditiesonhospitalisedsyrianpatientswithcovid19aretrospectivestudy
AT aljbawiahmad impactofcomorbiditiesonhospitalisedsyrianpatientswithcovid19aretrospectivestudy
AT alawadyara impactofcomorbiditiesonhospitalisedsyrianpatientswithcovid19aretrospectivestudy
AT mohsenfatema impactofcomorbiditiesonhospitalisedsyrianpatientswithcovid19aretrospectivestudy